Drug news
FDA approves Brisdelle (Noven Pharma) to treat hot flushes associated with Menopause
The FDA on 28 June 2013 approved Brisdelle (paroxetine)to treat moderate to severe hot flashes (vasomotor symptoms associated with Menopause). Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only non-hormonal treatment for hot flashes approved by the FDA. There are a variety of FDA-approved treatments for hot flashes, but all contain either estrogen alone or estrogen plus a progestin. Launch in the US is planned for November 2013.